ClinicalTrials.gg
CompletedNCT01984788OPuS-1Updated Aug 18, 2014

Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE

A Phase 2 interventional study of BCX4161 and Placebo in Hereditary Angioedema, sponsored by BioCryst Pharmaceuticals. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-18.

Sponsored by BioCryst Pharmaceuticals · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.

Enrollment
16th of 21
24 · median 54
Started
2013
the only one that year
Phase 2
4 of 22
none open now
Registered
1st of 22
by date

Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 2, and was the 1st registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic treatment is safe and effective in reducing the number of acute attacks in patients with hereditary angioedema.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • Oral Prophylaxis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Written
  • Clinical and laboratory diagnosis of Hereditary Angioedema Type I or II
  • An average angioedema attack frequency of 1/week
  • Acceptable measures

Key Exclusion Criteria:

  • Concurrent use of defined treatments for prophylaxis
  • Pregnancy or breast-feeding
  • medical condition, laboratory abnormality or medical history
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    BCX4161

    400 mg TID for 28 days

    Drug: BCX4161

  • Placebo comparator
    Placebo

    TID for 28 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of acute angioedema attacks

    Time frame: Over 28 days of treatment

Secondary outcomes

  1. Incidence and severity of adverse events and laboratory abnormalities

    Time frame: Over 28 days of treatment

  2. Number of attack free days

    Time frame: Over 28 days of treatment

  3. Angioedema Quality of Life scores

    Time frame: Over 28 days of treatment

  4. Angioedema activity scores

    Time frame: Over 28 days of treatment

07

Study locations

6 sites
  • Dr Marcus Maurer
    Berlin, Germany
  • Dr Emel Aygoren-Pursun
    Frankfurt, Germany
  • Dr Petra Staubach
    Mainz, Germany
  • Dr Inmaculada Martinez-Saguer
    Morfelden-Walldorf, Germany
  • Dr Murat Bas
    Munchen, Germany
  • Dr Hilary Longhurst
    London, United Kingdom
08

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2013
First posted
Nov 15, 2013
Start
Nov 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results delay requested
Aug 14, 2014
Last update
Aug 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01984788
Responsible party
Sponsor
First posted
Nov 15, 2013
Start date
Nov 2013
Primary completion
May 2014
Completion
May 2014
Last update
Aug 18, 2014

Study contacts

Marcus Maurer, MD
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avoralstat

Start the discussion